Vaccine development for rheumatoid arthritis

Malemud, Charles J.

doi:10.15761/gvi.1000102

Cited by 5 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been numerous vaccination strategies that are targeting collagens or the related peptides [ 133 ]. Substantial animal studies have been conducted on these collagen-targeting therapeutic vaccines including anti-collagen [ 134 ], CTAIR7K-COL-DD [ 135 ], CEL-2000 [ 136 ] and GalOK264/Aq [ 137 ].…”

Section: Immune Cell Related Biomarker and Vaccine Development Formentioning

confidence: 99%

“…Substantial animal studies have been conducted on these collagen-targeting therapeutic vaccines including anti-collagen [ 134 ], CTAIR7K-COL-DD [ 135 ], CEL-2000 [ 136 ] and GalOK264/Aq [ 137 ]. Note worthily, CEL-2000 was developed using Ligand Epitope Antigen Presentation System (LEAPS) technology which is a hetero-conjugate containing immune cell binding ligand (ICBL) attached to the antigenic peptide [ 131 , 133 ]. LEAPS has also been used to develop antigen-specific T-cell modulating vaccines such as CTAIR7K-COL-DD [ 135 ] and gal-CII259-273 [ 137 ].…”

Section: Immune Cell Related Biomarker and Vaccine Development Formentioning

confidence: 99%

See 1 more Smart Citation

Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development

Yap

Tee

Wong

et al. 2018

Cells

350

242

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, inflammatory disorder that affects synovial joints, both small and large joints, in a symmetric pattern. This disorder usually does not directly cause death but significantly reduces the quality of life and life expectancy of patients if left untreated. There is no cure for RA but, patients are usually on long-term disease modifying anti-rheumatic drugs (DMARDs) to suppress the joint inflammation, to minimize joint damage, to preserve joint function, and to keep the disease in remission. RA is strongly associated with various immune cells and each of the cell type contributes differently to the disease pathogenesis. Several types of immunomodulatory molecules mainly cytokines secreted from immune cells mediate pathogenesis of RA, hence complicating the disease treatment and management. There are various treatments for RA depending on the severity of the disease and more importantly, the patient’s response towards the given drugs. Early diagnosis of RA and treatment with (DMARDs) are known to significantly improve the treatment outcome of patients. Sensitive biomarkers are crucial in early detection of disease as well as to monitor the disease activity and progress. This review aims to discuss the pathogenic role of various immune cells and immunological molecules in RA. This review also highlights the importance of understanding the immune cells in treating RA and in exploring novel biomarkers.

show abstract

Section: Immune Cell Related Biomarker and Vaccine Development Formentioning

confidence: 99%

Section: Immune Cell Related Biomarker and Vaccine Development Formentioning

confidence: 99%

Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development

Yap

Tee

Wong

et al. 2018

Cells

350

242

View full text Add to dashboard Cite

show abstract

“…Citrullinated histones are associated with inflammatory neo-epitope expression in the immune system, further producing autoantibodies. Masking these new epitopes by therapeutic antibodies may reduce joint inflammation. , Citrullinated proteins may also be a potential target for vaccine design since neo-epitopes of the citrullinated proteins could be targeted before the severe stage of RA by using specific vaccines. , …”

Section: Cellular and Molecular Targets In Rheumatoid Arthritismentioning

confidence: 99%

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

Khokhar,

Dey,

Tomo

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease, that causes joint damage, deformities, and decreased functionality. In addition, RA can also impact organs like the skin, lungs, eyes, and blood vessels. This autoimmune condition arises when the immune system erroneously targets the joint synovial membrane, resulting in synovitis, pannus formation, and cartilage damage. RA treatment is often holistic, integrating medication, physical therapy, and lifestyle modifications. Its main objective is to achieve remission or low disease activity by utilizing a “treat-to-target” approach that optimizes drug usage and dose adjustments based on clinical response and disease activity markers. The primary RA treatment uses disease-modifying antirheumatic drugs (DMARDs) that help to interrupt the inflammatory process. When there is an inadequate response, a combination of biologicals and DMARDs is recommended. Biological therapies target inflammatory pathways and have shown promising results in managing RA symptoms. Close monitoring for adverse effects and disease progression is critical to ensure optimal treatment outcomes. A deeper understanding of the pathways and mechanisms will allow new treatment strategies that minimize adverse effects and maintain quality of life. This review discusses the potential targets that can be used for designing and implementing precision medicine in RA treatment, spotlighting the latest breakthroughs in biologics, JAK inhibitors, IL-6 receptor antagonists, TNF blockers, and disease-modifying noncoding RNAs.

show abstract

“…Most importantly, the development of “Rheumavax” has been evaluated with promising results in a phase I RA clinical trial. Rheumavax is also the first and only trial existing in humans ( 78 ).…”

Section: Targeted Acpa Therapymentioning

confidence: 99%

Anti-citrullinated Protein Antibody Generation, Pathogenesis, Clinical Application, and Prospects

Liu

Gao

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Anti-citrullinated protein antibodies (ACPAs) are autoantibodies commonly observed in patients with rheumatoid arthritis (RA). Currently, most of the mechanisms of ACPA formation and bone destruction are well-understood, however, some unknown mechanisms still exist. There have been many new advances in ACPA-related clinical applications and targeted therapies. However, the existence of different ACPA subtypes is a limitation of targeted therapy. Herein, we present an overview of the process of ACPA generation, the underlying pathogenesis, and relevant clinical application and prospects.

show abstract

Vaccine development for rheumatoid arthritis

Cited by 5 publications

References 50 publications

Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development

Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

Anti-citrullinated Protein Antibody Generation, Pathogenesis, Clinical Application, and Prospects

Contact Info

Product

Resources

About